Anti-Alpha V Immunoliposome Composition, Methods, and Uses
First Claim
1. An antibody derived targeting-ligand capable of monovalent binding and having specificity for alpha V integrin comprising:
- (a) a first polypeptide domain comprising the light chain variable region of a parent monoclonal antibody having specificity for alpha V-integrin or a conservative modification or fragment thereof that retains the binding specificity;
(b) a second polypeptide domain comprising the heavy chain variable region of a parent monoclonal antibody having specificity for alpha V-integrin or a conservative modification or fragment thereof that retains the binding specificity; and
wherein the targeting ligand retains specificity for at least one alphaV integrin.
1 Assignment
0 Petitions
Accused Products
Abstract
An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.
-
Citations
29 Claims
-
1. An antibody derived targeting-ligand capable of monovalent binding and having specificity for alpha V integrin comprising:
-
(a) a first polypeptide domain comprising the light chain variable region of a parent monoclonal antibody having specificity for alpha V-integrin or a conservative modification or fragment thereof that retains the binding specificity; (b) a second polypeptide domain comprising the heavy chain variable region of a parent monoclonal antibody having specificity for alpha V-integrin or a conservative modification or fragment thereof that retains the binding specificity; and
wherein the targeting ligand retains specificity for at least one alphaV integrin. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
-
Specification